Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study Finds

TUESDAY, Aug. 20, 2024 -- Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes by 94%, a new trial shows. The three-year-long...